Literature DB >> 30730275

Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases.

Rossella Talotta1,2, Francesco Rucci1,2, Gianfranco Canti3, Francesco Scaglione4,5.   

Abstract

The aim of this review is to report the current evidence on immunogenicity of monoclonal antibodies (moAbs) used in cancer compared with autoimmune diseases, focusing on local microenvironment. English abstracts were identified in Medline and www.clinicaltrials.gov . A total of 82 papers were selected. The percentage of immunogenicity of moAbs used for cancer therapy, evaluated as the serum concentration of antidrug antibodies, is significantly lower than that of moAbs used for the treatment of autoimmune diseases. This condition may rely on a different immunologic background characterized by a hyperactivation of immune cells in autoimmune diseases. The formation of complexes between antidrug antibodies and non-neutralizing moAbs bound to neoplastic antigens may allow more efficient elimination of cancer cells, but additional studies are needed.

Entities:  

Keywords:  autoimmune diseases; cancer; immunogenicity; microenvironment; monoclonal antibodies

Mesh：

Substances：

Year:  2019        PMID： 30730275     DOI： 10.2217/imt-2018-0081

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  7 in total

Review 1.  Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody.

Authors:  Robert Kernstock; Gizette Sperinde; Deborah Finco; Roslyn Davis; Diana Montgomery
Journal:  AAPS J       Date:  2020-03-17       Impact factor: 4.009

2.  Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells.

Authors:  Sivan Cohen; Srividya Myneni; Anna Batt; Joyce Guerrero; Jochen Brumm; Shan Chung
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

3.  Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.

Authors:  Jie Wang; Keke Fei; Hua Jing; Zhihai Wu; Weiwei Wu; Shuaixiang Zhou; Haiqing Ni; Bingliang Chen; Yan Xiong; Yanpeng Liu; Bo Peng; Dechao Yu; Haiping Jiang; Junjian Liu
Journal:  MAbs       Date:  2019-09-03       Impact factor: 5.857

4.  Aesthetic Treatments in Cancer Patients.

Authors:  Ilaria Proietti; Nevena Skroza; Alessandra Mambrin; Federica Marraffa; Ersilia Tolino; Nicoletta Bernardini; Anna Marchesiello; Giovanni Rossi; Salvatore Volpe; Concetta Potenza
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-12-04

Review 5.  Toward Overcoming Treatment Failure in Rheumatoid Arthritis.

Authors:  Zhuqian Wang; Jie Huang; Duoli Xie; Dongyi He; Aiping Lu; Chao Liang
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

6.  An integrated approach for characterizing immunogenic responses toward a bispecific antibody.

Authors:  Sivan Cohen; Shan Chung; Christoph Spiess; Victor Lundin; Eric Stefanich; Steven T Laing; Vanessa Clark; Jochen Brumm; Ying Zhou; Catherine Huang; Joyce Guerrero; Srividya Myneni; Rajbharan Yadav; Ketevan Siradze; Kun Peng
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 7.  The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies.

Authors:  Anna Vaisman-Mentesh; Matias Gutierrez-Gonzalez; Brandon J DeKosky; Yariv Wine
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.